A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies

Tan, AR; Chan, N; Kiesel, BF; Stein, MN; Moss, RA; Malhotra, J; Aisner, J; Shah, M; Gounder, M; Lin, HX; Kane, MP; Lin, Y; Ji, JP; Chen, A; Beumer, JH; Mehnert, JM

Tan, AR (通讯作者)，Atrium Hlth, Levine Canc Inst, 1021 Morehead Med Dr, Charlotte, NC 28204 USA.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022; 89 (1): 49

Abstract

Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索